目的 探讨翁沥通胶囊联合坦索罗辛治疗前列腺增生症的临床疗效。方法 选取2019年4月—2020年4月南阳市肿瘤医院收治的82例前列腺增生症患者为研究对象，随机分为对照组和治疗组（每组各41例）。对照组口服盐酸坦索罗辛缓释胶囊，0.2 mg/次，1次/d；治疗组在对照组基础上口服翁沥通胶囊，1.2 g/次，2次/d。两组均连续治疗12周。比较两组的临床疗效，观察两组相关量表评分、彩超多普勒超声指标、血清学因子的变化情况。结果 治疗后，治疗组总有效率是97.56%，显著高于对照组的82.93%（P<0.05）。经治疗，两组国际前列腺症状（IPSS）评分、中医症候评分均较治疗前显著降低，但国际勃起功能（ⅡEF-5）评分、生活质量（QOL）评分均显著升高（P<0.05）；治疗后，治疗组IPSS评分、中医症候评分低于对照组，而ⅡEF-5评分、QOL评分高于对照组（P<0.05）。经治疗，两组前列腺体积（PV）、残余尿量（PVR）均显著降低，而最大尿流率（Q_max）、显著升高（P<0.05）；治疗后，治疗组PV、PVR显著低于对照组，而Q_max高于对照组（P<0.05）。经治疗，两组血清缺氧诱导因子-1α（HIF-1α）、结缔组织生长因子（CTGF）、细胞凋亡抑制因子-2（Bcl-2）、胰岛样细胞生长因子-1（IGF-1）均较治疗前显著降低，但转化生长因子β1（TGF-β1）显著升高（P<0.05）；治疗后，治疗组HIF-1α、CTGF、Bcl-2、IGF-1低于对照组，而TGF-β1高于对照组（P<0.05）。结论 翁沥通胶囊联合坦索罗辛治疗前列腺增生症可有效改善患者下尿路症状，改善机体HIF-1α、CTGF、Bcl-2、TGF-β1、IGF-1水平，有利于提高患者生活质量和改善患者残余尿量及缩小前列腺体积，有着良好临床应用价值。

Objective To investigate the clinical efficacy of Wenglitong Capsules combined with tansulosin hydrochloride in treatment of benign prostatic hyperplasia. Methods A total of 82 patients with benign prostatic hyperplasia who were treated in Nanyang Cancer Hospital from April 2019 to April 2020 were selected as the research subjects and randomly divided into control group and treatment group (41 cases in each group). Patients in the control group were po administered with Tamsulosin Hydrochloride Sustained Release Capsules, 0.2 mg/time, once daily. Patients in the treatment group were po administered with Wenglitong Capsules on the basis of the control group, 1.2 g/time, twice daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, and the changes of related scale scores, color Doppler ultrasonography and serological factors were observed in the two groups. Results After treatment, the total effective rate of the treatment group was 97.56%, which was significantly higher than that of the control group (82.93%, P<0.05). After treatment, international prostate symptom (IPSS) score and TCM symptom score were significantly decreased in both groups, but international erectile function (ⅡEF-5) score and quality of life (QOL) score were significantly increased (P<0.05). After treatment, IPSS score and TCM syndrome score in the treatment group were lower than those in the control group, while ⅡEF-5 score and QOL score were higher than those in the control group (P<0.05). After treatment, PV and PVR in both groups were significantly decreased, while Q_max was significantly increased (P<0.05). After treatment, PV and PVR in the treatment group were significantly lower than those in the control group, while Q_max in the treatment group was higher than those in the control group (P<0.05). After treatment, serum hypoxia inducible factor-1α (HIF-1α), connective tissue growth factor (CTGF), apoptosis inhibitor factor-2 (Bcl-2) and islet like cell growth factor-1 (IGF-1) were significantly decreased, but transforming growth factorβ1 (TGF-β1) was significantly increased in both groups (P < 0.05). After treatment, HIF-1α, CTGF, Bcl-2 and IGF-1 in treatment group were lower than those in control group, while TGF-β1 was higher than those in control group (P<0.05). Conclusion Wenglitong Capsules combined with tansulosin hydrochloride can effectively improve the symptoms of patients with lower urinary tract in treatment of benign prostatic hyperplasia, also can improve the levels of HIF-1α, CTGF, Bcl-2, TGF-β1 and IGF-1, which is conducive to improve the life quality of patients, improve the residual urine volume and reduce the size of the prostate, and which has good clinical application value.

R983